FREMONT, Calif., May 21 /PRNewswire/ -- ViOptix Inc. announced today that Mr. Jack Lloyd has been elected to the Company's Board of Directors.
Mr. Lloyd has served as a founder, officer, and Director of medical and high technology companies since 1970. He was co-founder of Nellcor, the developer of Pulse Oximetry, and served as its first President and Chief Executive Officer from 1981-1990, during which time he grew the company from a start-up to annual sales of $150 million. Prior to his experience with Nellcor, from 1974 to 1981, Mr. Lloyd was founder and President of Humphrey Instruments, later acquired by Karl Zeiss. More recently, Mr. Lloyd served as Chairman and President of Aradigm Inc., a developer of aerosol drug delivery systems, from 1993 to 1997. He is also the founder and currently Chairman of Alere Medical Inc., a provider of disease management services utilizing electronic home monitoring, sold to Inverness Medical in 2007.
"Jack Lloyd is a shining example of medical device entrepreneurship," said Larry C. Heaton II, Chairman, Chief Executive Officer and President of ViOptix Inc. "We are honored that he will be joining us and delighted that we will have the benefit of his strategic insight and market development experience as we continue on the path of commercial growth."
"I am pleased to be working with a company addressing the needs of underserved patient populations," commented Mr. Lloyd. "In addition, I have great regard for the professionalism and integrity of ViOptix' management team, and I am impressed by the level of commitment I see in their experienced Board of Directors. I look forward to helping ViOptix achieve its mission of developing additional clinical applications from its core platform technology."
Mr. Lloyd holds a Bachelor's degree in mechanical engineering from the University of California, Berkeley. He serves on the Engineering Advisory Board of the UC Berkeley School of Engineering, and was recognized as a Notable Alumni for 2008.
About ViOptix Inc.
ViOptix Inc. develops, manufactures and markets innovative proprietary products for measuring oxygen saturation levels in tissues. The Company's products and products under development consist of near infrared generators and single-use disposable sensor devices. Its first product, the ODISsey System, received U.S. Food and Drug Administration clearance in January 2005 for the measurement of localized tissue oxygenation levels for critical care applications. For more information on the Company or its products, visit the Company's website at http://www.vioptix.com.
CONTACT: Larry C. Heaton II, President and Chief Executive Officer of
ViOptix Inc., +1-510-226-5860, ext. 202, heatonl@ViOptix.com
Web site: http://www.vioptix.com/